These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37962082)
1. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy. Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474 [TBL] [Abstract][Full Text] [Related]
3. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554 [TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090 [TBL] [Abstract][Full Text] [Related]
5. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy. Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446 [TBL] [Abstract][Full Text] [Related]
6. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature. Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H Front Immunol; 2022; 13():1063986. PubMed ID: 36713414 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579 [TBL] [Abstract][Full Text] [Related]
8. Impact of Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. Song F; Hu Y; Zhang Y; Zhang M; Yang T; Wu W; Huang S; Xu H; Chang AH; Huang H; Wei G J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808074 [TBL] [Abstract][Full Text] [Related]
10. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487 [TBL] [Abstract][Full Text] [Related]
12. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260 [TBL] [Abstract][Full Text] [Related]
13. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia. Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687 [TBL] [Abstract][Full Text] [Related]
14. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Tong C; Zhang Y; Liu Y; Ji X; Zhang W; Guo Y; Han X; Ti D; Dai H; Wang C; Yang Q; Liu W; Wang Y; Wu Z; Han W Blood; 2020 Oct; 136(14):1632-1644. PubMed ID: 32556247 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma]. Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437 [No Abstract] [Full Text] [Related]
16. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148 [TBL] [Abstract][Full Text] [Related]
17. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107 [TBL] [Abstract][Full Text] [Related]
19. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862 [TBL] [Abstract][Full Text] [Related]
20. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. Mercadal S; Gomez CA; Lee CJ; Couriel DR Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]